Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms
Open Access
- 1 December 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 182 (12) , 1321-1323
Abstract
Direct-to-consumer (DTC) online platforms can expand access to health care screenings and prescription medications. These platforms may be particularly advantageous for men’s health issues, such as erectile dysfunction, androgenic alopecia, and male infertility, because stigma may prevent men from seeking in-person evaluation for these issues. Accordingly, DTC men’s health platforms have seen exponential growth even prior to the COVID-19 pandemic, with a 1500% increase in online visits to DTC platforms treating erectile dysfunction from 2017 to 2019.1 Recently, given increased prescriptions for testosterone therapy and associated spending of over $400 million in the US, several new DTC testosterone therapy platforms have emerged.2,3 However, unlike pharmacotherapy for erectile dysfunction and androgenic alopecia, testosterone is a Class III controlled substance associated with increased risk of infertility, polycythemia, and possibly cardiovascular events, with the latter prompting multiple safety communications from the US Food and Drug Administration.4 Given the potential risks of testosterone therapy, we sought to examine whether DTC platforms provide appropriate, guideline-concordant care for testosterone therapy.Keywords
This publication has 6 references indexed in Scilit:
- Examining Online Traffic Patterns to Popular Direct-To-Consumer Websites for Evaluation and Treatment of Erectile DysfunctionSexual Medicine, 2021
- Trends in Testosterone Prescribing for Age-related Hypogonadism in Men With and Without Heart DiseaseJAMA Internal Medicine, 2019
- Evaluation and Management of Testosterone Deficiency: AUA GuidelineJournal of Urology, 2018
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2018
- Trends in Testosterone Replacement Therapy Use from 2003 to 2013 among Reproductive-Age Men in the United StatesJournal of Urology, 2017
- Re: Testosterone Products: Drug Safety Communication - FDA Cautions about Using Testosterone Products for Low Testosterone due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and StrokeJournal of Urology, 2015